Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China by Asia Insider June 18, 2020 June 18, 2020 0 FacebookTwitterPinterestLinkedinRedditEmail
